SoftBank’s SB Management subsidiary, Illumina and Novartis are backing a $375m PIPE supporting the deal, which values the proteomics technology provider at $1.23bn.

SomaLogic, the US-based healthcare management software provider backed by Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics, agreed a reverse takeover on Monday with special purpose acquisition company CM Life Sciences II. The deal gives SomaLogic a pre-transaction enterprise value of approximately $1.23bn and will involve it acquiring the spot on the Nasdaq Capital Market…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.